The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the
Approval is Second Middle East Country to Approve Vascepa Sale Following Lebanon Earlier This Year BEDMINSTER, N.J. and DUBLIN, Ireland , July 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of
BEDMINSTER, N.J. and DUBLIN, Ireland , July 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with
Study Remains On-Track for Q3 2018 Top-Line Results BEDMINSTER, N.J. , and DUBLIN, Ireland , June 28, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today
Data Underscores the Need for the REDUCE-IT™ Cardiovascular Outcomes Study BEDMINSTER, N.J. and DUBLIN, Ireland , June 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve
BEDMINSTER, N.J. and DUBLIN, Ireland , June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted
BEDMINSTER, N.J. and DUBLIN, Ireland , June 07, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific
BEDMINSTER, N.J. and DUBLIN, Ireland , May 24, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today a settlement agreement with Teva
BEDMINSTER, N.J. , and DUBLIN, Ireland , May 23, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
REDUCE-IT Study On-Track for Reporting Top-Line Results by the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. and DUBLIN, Ireland , May 02, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the